8-K: Zura Bio Appoints Eric Hyllengren as New Chief Financial Officer, Verender Badial Steps Down

Zura Bio Limited announced the appointment of Eric Hyllengren as its new Chief Financial Officer, effective July 7, 2025, succeeding Verender Badial who will transition out of the role.

Summary

• Zura Bio Limited appointed Eric Hyllengren as Chief Financial Officer (principal accounting and principal financial officer), effective July 7, 2025.
• Mr. Hyllengren, age 50, previously served as Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. and held various leadership roles at Amgen Inc.
• His compensation includes an annual base salary of $475,000 and eligibility for a discretionary annual cash bonus with a target of 40% of his base salary.
• Mr. Hyllengren will receive an option to purchase 672,000 Class A ordinary shares, vesting over 4 years, with 25% vesting on the first anniversary of the effective date and the remainder in equal quarterly installments over the following three years.
• Verender Badial resigned from his position as Chief Financial Officer, effective July 7, 2025, and will remain with the company as a non-executive employee through July 31, 2025, to assist with the transition.
• Mr. Badial's transition is unrelated to the company's financial results or any disagreement over accounting principles, practices, or financial disclosures.
• Pursuant to a settlement agreement, Mr. Badial will receive a cash severance payment of $178,294.92, a cash payment in lieu of notice of $89,147.46, a cash payment of $23,500.11 for accrued but untaken holiday, a $4,000 cash payment for 12 months of private health insurance premiums, and a reimbursement of up to $27,000 for transition assistance.
• The settlement agreement also provides for accelerated vesting of the unvested portion of two outstanding options granted to Mr. Badial on May 18, 2023 (107,811 shares) and June 18, 2024 (78,750 shares), relating to nine additional months of vesting.
• Options previously granted to Mr. Badial on May 8, 2025, covering 303,100 Class A ordinary shares, will be immediately forfeited upon his separation date.
• A press release regarding these management changes was issued on July 1, 2025.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced CFO from well-regarded biotech companies, coupled with a smooth transition and explicit statement that the change is not due to financial or accounting disagreements, indicates a strong positive development for the company's leadership and strategic direction.

Positives

• Appointment of Eric Hyllengren, an experienced financial leader with over 20 years in life sciences and biotechnology, including significant roles at Atara Biotherapeutics and Amgen Inc.
• Mr. Hyllengren's background in strategic finance, capital markets, cost transformation, and organizational design is expected to support Zura Bio's ongoing growth and operational execution.
• The company explicitly stated that the outgoing CFO's transition is unrelated to its financial results or any disagreements over accounting principles, practices, or financial disclosures, indicating a planned and amicable change.
• The outgoing CFO, Verender Badial, will remain with the company as a non-executive employee until July 31, 2025, to ensure a smooth and seamless transition of responsibilities.

Negatives

• The outgoing CFO, Verender Badial, will immediately forfeit options covering 303,100 Class A ordinary shares granted on May 8, 2025.
• Shares acquired by Mr. Badial through the exercise of accelerated options will be subject to transfer restrictions, with one-third transferable after the first, second, and third anniversaries of the Separation Date, respectively.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expected results, including factors set forth in Zura Bio's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, and other SEC filings.

Future Outlook

Zura Bio expects Eric Hyllengren's broad financial expertise and deep sector experience to support its ongoing growth and operational execution, and to help build strong relationships with stakeholders as it pursues its long-term goals. The company's pipeline includes dual-pathway product candidates, with tibulizumab (ZB-106) currently in two Phase 2 clinical studies and crebankitug (ZB-168) and torudokimab (ZB-880) having completed Phase 1/1b studies, indicating continued progress in its clinical development program.

Management Comments

• "I am excited to welcome Eric to our leadership team. His broad financial expertise, combined with deep sector experience, makes him a strong strategic partner. We're confident he will elevate our leadership team and continue building the strong relationships we've established with our stakeholders as we pursue our long-term goals." Robert Lisicki, Chief Executive Officer of Zura Bio.
• "On behalf of the Board, we thank Verender for his contributions and wish him well in his future endeavors." Robert Lisicki, Chief Executive Officer of Zura Bio.
• "Being part of Zura Bio's mission has been both rewarding and meaningful. I am proud of what we've accomplished and grateful to have worked alongside such talented and dedicated colleagues. I look forward to supporting a smooth transition." Verender Badial.

Industry Context

The appointment of a new Chief Financial Officer with extensive experience in the life sciences and biotechnology sectors, particularly from established companies like Amgen and Atara Biotherapeutics, aligns with a common industry trend where growing clinical-stage companies seek seasoned financial leadership. This move is crucial for navigating complex capital markets, managing operational costs, and supporting strategic growth initiatives, which are critical steps for biotech firms transitioning through clinical phases towards potential commercialization.

Comparison to Industry Standards

• Eric Hyllengren's background at Atara Biotherapeutics (Nasdaq: ATRA), a clinical-stage T-cell immunotherapy company, and Amgen Inc. (Nasdaq: AMGN), a large, established biotechnology company, provides a strong qualitative benchmark. His experience in strategic finance, capital markets, and business development at these firms suggests a profile well-suited for a clinical-stage immunology company like Zura Bio, which is focused on advancing its pipeline (tibulizumab, crebankitug, torudokimab).
• The compensation package for the new CFO, including a base salary of $475,000 and a target bonus of 40%, along with a significant equity grant of 672,000 shares, appears competitive for a CFO role at a Nasdaq-listed clinical-stage biotech company, aiming to attract top-tier talent from larger, more established firms.
• The severance package for the outgoing CFO, including cash payments and accelerated vesting of some options, is a standard practice in executive transitions, designed to ensure a smooth departure and release of claims, aligning with typical industry practices for executive separations.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a highly experienced CFO could be viewed positively, potentially enhancing investor confidence in the company's financial management and strategic execution. The forfeiture of some options by the outgoing CFO could be seen as a minor positive for dilution control, while the accelerated vesting of others is a cost of the transition.
• Employees: A new CFO may bring new financial strategies or operational efficiencies, potentially impacting internal processes. The smooth transition plan for the outgoing CFO suggests a focus on continuity and stability within the organization.
• Customers/Suppliers: Unlikely to have a direct immediate impact from a CFO change, but improved financial stability and strategic direction under new leadership could indirectly benefit long-term business relationships.
• Creditors: Stronger financial leadership could improve the company's creditworthiness and ability to manage debt, if applicable, potentially leading to more favorable terms for future financing.

Next Steps

• Eric Hyllengren to commence employment as Chief Financial Officer on July 7, 2025.
• Grant of an option to purchase 672,000 Class A ordinary shares to Mr. Hyllengren as soon as practicable following July 7, 2025.
• Mr. Hyllengren and the Company to enter into the Company's standard indemnification agreement and Employee Confidential Information and Inventions Assignment Agreement on July 7, 2025.
• Verender Badial to remain with the Company as a non-executive employee through July 31, 2025, to assist with the transition.
• Verender Badial to sign a Reaffirmation Letter on or within seven days following July 31, 2025.

Key Dates

Recommendation

Keywords

Zura Bio, CFO, Chief Financial Officer, Eric Hyllengren, Verender Badial, management change, executive appointment, biotechnology, life sciences, SEC filing, 8-K, corporate governance, financial leadership, stock options, severance